DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Tegafur is an investigational drug.
There have been 124 clinical trials for Tegafur. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2014.
The most common disease conditions in clinical trials are Stomach Neoplasms, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are Fudan University, Taiho Oncology, Inc., and National Cancer Institute (NCI).
There are two US patents protecting this investigational drug and twenty-nine international patents.
Recent Clinical Trials for Tegafur
|CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer||Peking Union Medical College Hospital||Phase 1/Phase 2|
|SBRT With S1 Combined With Endostar in the Treatment of Lung Cancer||Beijing Cancer Hospital||N/A|
|SBRT With S1 Combined With Endostar in the Treatment of Lung Cancer||Cancer Institute and Hospital, Chinese Academy of Medical Sciences||N/A|
Top disease conditions for Tegafur
Top clinical trial sponsors for Tegafur
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tegafur||Start Trial||Heterocyclic compounds useful in the treatment of disease||Epigen Biosciences, Inc. (San Diego, CA)||Start Trial|
|Tegafur||Start Trial||Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same||Protalix Ltd. (Carmiel, IL)||Start Trial|
|Tegafur||Start Trial||Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof||The Regents of the University of California (Oakland, CA)||Start Trial|
|Tegafur||Start Trial||Nuclear targeting sequences||Yeda Research and Development Co. Ltd. (Rehovot, IL)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|